 Professor Adrian Begg
Department Molecular Radiobiology
The Netherlands Cancer Institute
The Netherlands
Adrian Begg carried out his PhD research at the University of London, firstly within Hammersmith Hospital and subsequently at the Cancer Research Campaign Gray Laboratory. He studied the cell kinetics of murine tumors in relation to their radiation response under the supervision of Jack Fowler. He then held a 3-year post-doctoral position at the University of California Medical Center, San Francisco, studying the interaction of cytotoxic drugs and radiation, under Ted Phillips and Karen Fu. This was followed by a return to the Gray Laboratory as group head for a five year period where he pursued drug-radiation interactions, and began his translational research interests (applying radiobiological principals in clinical trials) under both Jack Fowler and subsequently Julie Denekamp. He then moved to the Netherlands Cancer Institute in 1984 with Fiona Stewart, where they set up a radiobiology group with the support of Harry Bartelink. Flow cytometry was coming of age and he was one of the first to apply IUdR antibodies for the measurement of cell proliferation in clinical tumor samples to predict tumor response. He became head of the Experimental Therapy division in 1990, and Professor of Molecular Radiobiology attached to Radboud University Nijmegen in 2002. His present research focuses on predicting and improving response in head and neck cancer using several array and sequencing technologies (translational research), and elucidating the genetic determinants of radiosensitivity, particularly base excision repair, single strand break repair and translesional synthesis (fundamental research). The fundamental research lines have also led to potential clinical applications for improving radiotherapy, particularly exploiting repair deficiencies in tumors. He is a committed member and supporter of ESTRO, has been an ESTRO Board member, is a member of the ESTRO Radiobiology Committee, and has been on organizing committees of many ESTRO meetings including the Annual meetings, the former Biology Meetings, the present Wolfsberg meetings and the Toulouse meetings. He has also been a committed teacher both within in outside of ESTRO. He has taught on both the Basic Clinical Radiobiology and the Molecular Radiobiology courses, as well as organizing and/or teaching on several pre-meeting courses. To stimulate radiobiology within ESTRO, he writes a Radiobiology Corner column for the ESTRO Newsletter 3-4 times a year. He has 158 papers in peer reviewed journals, plus 19 book chapters.
Appointments
1968-1970 Scientific Officer, Hammersmith Hospital, London, England
1970-1975 Scientific Officer, Gray Laboratory, Northwood, England
1975-1978 Post Doctoral Fellow, University of California, San Francisco
1979-1983 Research Scientist, Gray Laboratory, Northwood, England
1984-1989 Head, Radiobiology Group, The Netherlands Cancer Inst
1990-2003 Head, Division of Experimental Therapy, The Netherlands Cancer Institute
2002-present Professor, Molecular Radiobiology, University of Nijmegen, Netherlands
 Professor Søren M Bentzen
Director of Research and Education of Human Oncology
University of Wisconsin School of Medicine and Public Health, Clinical Science Center, Madison Wisconsin, USA
Professor of Human Oncology, Professor of Medical Physics, Professor of Biostatistics & Medical Informatics, Varian Visiting Professor to the Radiation Therapy Oncology Group, Adjunct Professor of Radiobiology and Medical Physics
University of Copenhagen, Denmark
Søren M. Bentzen, PhD, DSc is professor of Human Oncology, and Director of Research and Education of Human Oncology, University of Wisconsin (UW) School of Medicine and Public Health, Madison, Wisconsin, USA. He leads the Imaging and Radiation Science program of the Carbone Comprehensive Cancer Center in Madison. Søren holds joint appointments as Professor of Medical Physics and of Biostatistics & Medical Informatics at UW. Qualifications: M.Sc. (physics and mathematics, 1981); Ph.D. (medical imaging, 1986); D.Sc. (clinical radiobiology, 1994), all from Aarhus University, Denmark.
Søren has published more than 330 papers and presented in excess of 260 invited lectures. He currently serves on 9 international cancer journal editorial boards and was recently elected member of the International Commission on Radiation Units and Measurements (ICRU). His research has been recognized by 20 awards and honors including the ESTRO Breuer Gold Medal (2003), the MD Anderson Distinguished Alumnus Award (2008), Honorary Life Memberships of Association of Radiation Oncologists of India (2008) and Belgian Society for Therapeutic Radiology and Oncology (2009). Søren held an Honorary Professorship at University College London (2000–2005). He is currently the Varian Visiting Professor to the Radiation Therapy Oncology Group (RTOG) and Adjunct Professor of Radiobiology and Medical Physics, University of Copenhagen.
Selected appointments: MD Anderson Cancer Center (1987-1988), Danish Cancer Society/Aarhus University (1988-1997), Gray Laboratory/Mount Vernon Hospital, London (1998-2004), UW School of Medicine and Public Health (2005–present)
Main research interests: late effects of radiotherapy, integration of data from genomics, proteomics and molecular imaging into novel radiation therapy strategies; evidence based medicine.
|
 Professor Patricia Eifel
Professor, Department of Radiation Oncology, Division of Radiation Oncology
The University of Texas MD Anderson Cancer Center, Houston, Texas
Dr Patricia Eifel studied at Stanford University, where she trained in radiation oncology. She has spent her professional career working in academic environments that have provided opportunity for the care for patients and to pursue interests in teaching and research. Dr. Eifel’s research and clinical activity has focused on cancers of the female genital tract. Her work at MD Anderson has led to detailed studies of the large clinical experiences with cervical, vaginal, and vulvar cancers that have documented the efficacy of radiation therapy and have suggested opportunities for improvements in locoregional control and survivors’ quality of life. Much of her work has focused on the use of multimodality treatments, particularly the use of combined chemotherapy and radiation in the treatment of cervical cancer. This work contributed to acceptance of combined chemoradiation as a standard of care for women with locoregionally advanced cervical cancer. In recent years, another research focus has been the implementation of modern imaging technology, IMRT, and image-based brachytherapy in the treatment of gynecologic cancers. Dr. Eifel is heavily involved in the administration of clinical cancer research. She currently serves as the Chief of the Gynecologic Radiation Oncology Service, and Chair of the Gynecology Research Steering Committee at MD Anderson. She has also served on the Board of the American Society for Radiation Oncology (ASTRO) and previously served as the society’s president.
|
